Applied BioCode Corporation is a public company in Taiwan (TWSE stock code 6598，ABC-KY) , has headquarters in US and Taiwan, and focuses on research, development, manufacture and commercialization of multiplex diagnostics products, targeting the 52BUSD In-Vitro Diagnostics market.

The company owns Barcoded Magnetic Beads (BMB) Technology and automated detection system. Together they enhance molecular and immuno assays with highly multiplex detection capability. BMB platform technology provides as many as 4,096 targets detection using bio compatible digital barcodes, with unparalleled identification accuracy. 

Applied BioCode's IVD products focus on the infectious disease segment, including US-FDA 510k cleared Gastrointestinal Pathogen Panel (GPP) and Respiratory Pathogen Panel (RPP), US and TW FDA EUA Cov-Flu-Plus assay, and Fungal Analyte Specific Reagents, STI+Resistence Panel. Applied BioCode also licenses BMB to 13 international partners to develop different applications, covering infectious disease, animal diagnostics, autoimmune disease, allergy, HLA typing, serology, HBV and HCV, gut health metabolism, and food safety.